Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J. Overman, Thierry André, Ray McDermott et al.|The Lancet Oncology|2017Cited by 2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Scott Kopetz et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018Jonathan M. Loree, Kanwal Raghav, Seerat Anand et al.|JAMA Oncology|2019Cited by 568
Clinical and molecular characterization of early‐onset colorectal cancerAlexandra N. Willauer, Jonathan M. Loree, Yusha Liu et al.|Cancer|2019Cited by 361
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M. Loree, Scott Kopetz, Allan Andresson Lima Pereira et al.|Clinical Cancer Research|2017Cited by 318